Brandenburg Kapital - News Adrenomed AG
Adrenomed completes full enrollment with 300 patients Phase II trial in early septic shock
Potsdam/Hennigsdorf - October 2019. Adrenomed AG, a pharmaceutical company focussed on the vascular integrity of blood vessels announced today the successful completion of patient enrollment with the last of the 300 patients in the proof-of-concept Phase II trial in early septic shock. The completion of the enrollment demonstrates an important step towards the development of the drug candidate. Final results of the study are expected in the first quarter of 2020.
About Adrenomed
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 300 patients suffering from septic shock. Excellent safety and tolerability were demonstrated in
two Phase I trials. For further information, please visit www.brandenburg-kapital.de or www.adrenomed.com
